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Frizzled is the earliest discovered glycosylated Wnt protein
receptor and is critical for the initiation of Wnt signaling.
Antagonizing Frizzled is effective in inhibiting the growth of
multiple tumor types. The extracellular N terminus of Frizzled
contains a conserved cysteine-rich domain that directly inter-
acts with Wnt ligands. Structure-based virtual screening and
cell-based assays were used to identify five small molecules that
can inhibit canonical Wnt signaling and have low IC50 values in
the micromolar range. NMR experiments confirmed that these
compounds specifically bind to theWnt binding site on the Friz-
zled8 cysteine-rich domain with submicromolar dissociation
constants. Our study confirms the feasibility of targeting the
Frizzled cysteine-rich domain as an effective way of regulating
canonical Wnt signaling. These small molecules can be further
optimized into more potent therapeutic agents for regulating
abnormal Wnt signaling by targeting Frizzled.
Wnt signaling controls cell fate, proliferation, migration, tis-
sue architecture, and organogenesis during embryonic devel-
opment (1–7). CanonicalWnt signaling is initiated by the bind-
ing of secreted Wnt proteins with the membrane co-receptors
LRP5/6 (low density lipoprotein receptor-related protein 5/6)
and FZD (Frizzled). Subsequent Dishevelled activation dissem-
bles the adenomatous polyposis coli/axin/glycogen synthase
kinase 3 complex, which results in -catenin accumulation
and the formation of -catenin/transcription factor complexes
in the nucleus, leading to the transcription of multiple down-
stream genes (8). Dysregulation of the canonical Wnt signaling
pathway has been observed in many diseases including bone
diseases, diabetes, and several types of cancer (9).
FZDs are G protein-coupled receptor-like proteins. They
consist of an extracellular N terminus containing a highly con-
served cysteine-rich domain (CRD; Fig. 1),4 a seven-transmem-
brane domain, and a cytoplasmic C terminus (10, 11). To date,
10 human FZDs, FZD1–FZD10, have been cloned and charac-
terized (10, 11). Wnt glycoproteins initiate Wnt signaling by
interacting with the FZD CRD, as well as with the extracellular
domains of LRP5/6 to form aWnt/FZD/LRP complex. sFRPYs
(secreted Frizzled-related proteins) inhibit Wnt signaling by
blocking the interaction betweenWnt proteins and FZDwith a
homologous CRD domain, demonstrating that FZD is a critical
target for upstream Wnt signaling regulation (12, 13). More-
over, because overexpression of FZD has been observed in
many cancers (14–19), the CRD has been proposed as a poten-
tial target for therapeutic development against cancer and
other human diseases. Indeed, it was shown that a monoclonal
antibody that targets the CRD domains of FZDs can block
canonical Wnt signaling induced by Wnt ligands and is able to
reduce the growth of different types of tumor (9).
Here, we report on the discovery of smallmolecule inhibitors
of the FZD8CRDusing a hybrid structure-based lead discovery
approach that combined molecular modeling, biophysical
methods, and a cell-based assay. The crystal structure of the
CRD ofmouse FZD8 has been reported, andmutagenesis stud-
ies identified the key residues for the FZDCRD binding toWnt
ligands (20). A recent x-ray structure of Xenopus Wnt8
(XWnt8) in complex with the mouse FZD8 CRD confirmed
that this site directly interacts with the XWnt8 ligand and plays
a key role in mediating Wnt signaling (20, 21). Based on the
structural information, several hierarchical virtual screening
(VS) simulations were conducted to select smallmolecule com-
pounds that can target theWnt binding site on the FZD8 CRD.
We tested 120 top ranked compounds for their inhibitory activ-
ities of canonical Wnt signaling by using a cell-based luciferase
reporter assay. Five compounds were shown to be strong inhib-
itors of canonical Wnt--catenin signaling. In addition, using
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NMR spectroscopy, we confirmed that these small molecule
compounds specifically bind, with lowmicromolar affinities, to
the Wnt/FZD binding site on the FZD8 CRD. Our work dem-
onstrates that interrupting the Wnt-FZD CRD interaction by
small molecules from structure based drug discovery is of
highly promising potential for the development of new thera-
peutics against diseases influenced by abnormalWnt signaling.
Experimental Procedures
Docking and Scoring inVirtual Screening—TheGlidemodule
in the Schro¨dinger packagewas used for the virtual screening of
the CRD ofmouse FZD8 (Frizzled8). Two small molecule data-
bases, National Cancer Institute plate 2007 (containing 117,500
compounds) andChemDiv (containing 1,414,174 compounds),
were used for structure-based virtual screening. The ChemDiv
database was prescreened using the UNITYmodule (Tripos) to
identify compounds that are potentially compatible with the
size and shape of the primary Wnt binding site on the mouse
FZD8 CRD (21). This procedure reduced the database size of
ChemDiv to 11,000 compounds. All selected compounds were
prepared using the LIGPREP module in the Schro¨dinger pack-
age (Schro¨dinger, New York, NY). The pH was set at 7.5, and
OPLS 2005 force field parameters were applied to all selected
small molecules. The receptor model was derived from the
mouse FZD8 CRD crystal structure (Protein Data Bank code
1IJY, chain A) (20) with removal of all water molecules. The
protein preparation script in MAESTRO (Schro¨dinger, New
York, NY) was used to add polar hydrogen atoms, partial
charges and fix errors in crystal structure. The molecular
mechanics force field grids around the space of primary Wnt
binding site were generated by Glide, and the virtual screening
was performed by Glide with standard precision. The com-
poundswith top predicted binding free energies and reasonable
binding orientations within the defined active site were subse-
quently obtained from NCI and ChemDiv for further evalua-
tion of the docking results (22).
Cell Culture—A stable transfected cell line expressing Lucif-
erase under a transcription factor (TCF)/LEF promoter was
used. 3T3 cells were maintained in 5% CO2 at 37 °C in Dulbec-
co’s modified Eagle’s medium containing 10% fetal bovine
serum, 4.5 g/liter D-glucose, 2mM glutamine, 0.1mMnonessen-
tial amino acids, 10 mM HEPES, 100 U/ml penicillin, and 100
g/ml streptomycin. Cells were seeded and grown overnight in
a 96-well plate at 4  105 cells/ml confluences. Wnt3a and
compounds (0–40 M) were dissolved in DMEM (Invitrogen)
assay media containing 0.5% FBS. The plate was divided
between two sections: one with 50 ng/ml of Wnt3a and a con-
trol with the assay media. Cells were incubated with protein
plus compound between 12 and 16 h before readings. Each
experiment was performed in duplicate for each compound.
Luciferase Assays—The Promega (Madison, WI) ONE-
GloTM Tox luciferase reporter and cell viability assay kit was
used tomeasure inhibition ofWnt signaling. In brief, cells were
first incubated for 30minwith a cell-permeant fluorogenic sub-
strate. In a living cell, the substrate is cleaved by a liver protease
that results in emission of fluorescence. This was used to nor-
malize for potential toxic effects of the ligands. Aftermeasuring
cell viability, 5-fluoroluciferin was added to the cells. In the
cells, the fluoroluciferin is cleaved by luciferase, which emits
luminescence. Both fluorescence and luminescence were mea-
sured using an EnVisionmicroplate reader. Analysis of inhib-
itors dose-response data and calculation of IC50 values were
performed using the program Origin.
Western Blotting Analysis—Human embryonic kidney cell
line (HEK293T) cells were seeded in 24-well plate at a density of
10 104 cells/well and cultured for 24 h. Cells were stimulated
byWnt3a conditionedmedium supplementedwith 10M indi-
vidual compounds or DMSO (control) for 3 h. Cells were lysed
in Nonidet P-40 buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM
EDTA, and 1% Nonidet P-40). Lysates were cleared by centrifu-
gation, and protein concentrations were determined by BCA
assay. Protein sampleswere dissolved on 6%SDS-PAGE gel and
then transferred to 0.45 m nitrocellular membranes. Mem-
braneswere blocked by 5%nonfatmilk and then incubatedwith
anti-phosphor-LRP6 (S1490) antibody (Cell Signaling Tech-
nology, Inc.; catalog no. 2568s) (1:2000) overnight at 4 °C, fol-
lowed by anti-rabbitHRP secondary antibody (1:2000) for 1 h at
FIGURE 1. Primary sequence alignment of mouse FZD CRDs. The sequence alignment was generated using ClustalW2.
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room temperature. The membranes were washed with TBST
for three times at room temperature. Finally, phosphor-LRP6
band was detected with the enhanced chemiluminescence sub-
strate (Thermo Fisher Scientific Inc.). Tubulin was used as the
loading control. ECL signal was calculated by using National
Institutes of Health ImageJ software.
Expression and Purification of the Mouse FZD8 CRD—The
mouse FZD8 CRD (Ala28–Asp155) was subcloned into pET28a
vector and was transformed into Rosetta2 (DE3) cells (Nova-
gen). The cells were grown inMOPSmedia supplemented with
[15N]ammonium chloride and [13C]glucose as the source of
nitrogen and carbon, respectively. The cells were grown to a
A600 value of 0.5  0.6 and induced with 1 mM isopropyl -D-
1-thiogalactopyranoside for 16 h at 37 °C with 200 rpm. The
target protein was expressed insolubly as inclusion bodies. To
denature the target protein, the pellet of 1 liter of Escherichia
coli cell culture was dissolved with 20 ml of 8 M urea with 100
mM-mercaptoethanol and thenwas refolded by rapid dilution
using 10 mM Tris, pH 9.0, with 50 mM Arg and 1 mM oxidized
glutathione. The protein was further purified byHPLC andwas
dialyzed in 50 mM potassium phosphate (pH 6.5 or 7.5) with 5
mM EDTA. The two-dimensional 1H-15N HSQC spectrum of
the purified 15N-labeled FZD8 CRD showed that the FZD8
CRD protein is folded (23).
Biolayer Interferometer (BLI) Experiments—The Octet RED
instrument (Forte´Bio) was used to measure the interaction of
mouse FZD8 CRD to the compounds identified from the both
the VS and the cell-based assays. Super streptavidin (SSA) sen-
sors were used to attach the biotinylated FZD8 CRD. Biotiny-
lation of FZD8 CRD was made by incubating 100 l of 2 mM
EZ-Link Sulfo-NHS-LC-Biotin (Thermo Scientific, catalog no.
21335) with 1ml of 8M FZD8CRD in 50mM potassium phos-
phate buffer, pH 6.5, for 4 h on a rocking platform at room
temperature. A desalting column was used to purify the bioty-
lated-FZD8 CRD. Before experiments, the SSA sensors were
preincubated for 10 min in 50mM potassium phosphate buffer,
pH 6.5, with 0.01% Tween 20, 5% DMSO, and 1 mg/ml BSA
(assay buffer). The biotinylated proteins were attached to the
SSA sensors for 10 min. The excess protein was removed by
washing with assay buffer for 20min. To determine the binding
affinity of mouse FZD8 CRD to the five compounds, several
concentrations of compounds were used. The association step
for 50 swas followed by the dissociation step for 100 s. Biocytin-
loaded SSA sensor without loading biotinylated protein was
used as a control to correct the systematic optical artifacts and
baseline drifts (24). All stepswere performed at 25 °Cwith 1,000
rpm rotary shaking. The processed data were fitted locally with
the integrated fitting function using the 1:1 binding model in
Forte´ Bio analysis software (v6.4). The kinetic constants kon (on
rate constant), koff (off rate constant), and KD were calculated
from curve fitting.
Preparation of Compound Solutions for NMR Studies—The
compounds were dissolved in DMSO-d6 to make 10 mM stock
solutions. To investigate physical properties, such as solubility
and self-aggregation, of compounds in aqueous buffer, wemade
a series of sampleswith various compound concentrations in 50
mM potassium phosphate at two different pHs, pH 6.5 and 7.5,
with 0.5mMEDTA, 10%D2O, and 5%DMSO-d6. Because of the
poor solubility of compounds, we were unable to make the
desired concentration of 12.5–200 M. We obtained one-di-
mensional 1H NMR spectra of each compound at various
desired concentrations. The peak intensity changes of reso-
nance for each compoundwere examined to determine the sol-
ubility, as well as visual inspection of precipitation of com-
pound in buffer. The solubility of compounds in the two
different buffers was examined.
NMR Experiments—All spectra were recorded using either
1H,15N-labeled or 1H-, 15N-, and 13C-labeled protein on Bruker
Avance 600- or 800-MHz NMR spectrometers equipped with
1H/15N/13Cdetect, triple resonance cryogenic inverse probes at
25 or 32 °C. All spectra were processed using Topspin 3.0 NMR
software (Bruker Biospin) and analyzed using the program
CARA (computer-aided resonance assignment). To assign the
backbone chemical shift of mouse FZD8 CRD, 200 M FZD8
CRDwas prepared in 50 mM potassium phosphate, pH 6.5, and
10%D2O (v/v).We performed two-dimensional 1H-15NHQSC
and three-dimensional HNCA, HNCOCA, CACB (CO)NH,
HNCACB, and 15N NOESY (mix time 120 ms) NMR exper-
iments at 32 °C.Chemical shift perturbation (CSP) experiments
were performed using 15N-labeledmouse FZD8CRD.The two-
dimensional 1H-15NHSQC (or 1H-15N fast HSQC) (25) spectra
were recorded as a function of concentration of compound. A
FIGURE 2. Residues and surface on the FZD8 CRD defined for virtual
screening. The residues critical for Wnt signaling activity are shown in
magenta, whereas the residues defined for UNITY searches are shown as
sticks (model derived from coordinates of Protein Data Bank code 4F0A). The
bound conformation of index finger loop region (amino acids 308–336) of
XWnt8, which is critical for Wnt-FZD CRD recognition (21), is shown in blue
cartoon for the validation of potential cavity determination.
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stock solution of 10 mM compound was made in DMSO-d6
for use in NMR titration experiments. The concentration of
DMSO in the NMR titration experiment was below 3%. A
control experiment was done by titrating 5% DMSO, which
did not show any structural change in this condition. The
chemical shift perturbation (, ppm) of 1H and 15N reso-
nances were obtained and weighted according to Equation 1.
  H	2  0.2*N	2 (Eq. 1)
Results
Hierarchical Structure-based VS for FZD 8 CRD Inhibitor
Discovery—The atomic structure of the FZD8 CRD was
reported previously, and the residues critical formediatingWnt
signaling were examined by mutagenesis experiments (20). It
was shown that Xenopus Wnt8 (XWnt8) binds to a cavity
formed by residues Ile46, Gly47, Tyr48, Ile95, Leu97, Gln141,
Gly142, Asn143, Pro144, Asp145, Thr146, Leu147, Met149, Asp150,
and Tyr151 of the mouse FZD8 CRD, which is located at the
FZD8 CRD dimerization interface in the crystal structure (Pro-
tein Data Bank code 1IJY). A recent x-ray structure of theWnt-
FZD CRD complex confirmed that this cavity directly binds to
a loop structure known as the “index finger” region on theWnt8
protein (21) (Fig. 2). Based on the available structural informa-
tion, hierarchical structure-based VS utilizing the UNITY
module in the SYBYL package (Tripos, Inc.) and Glide
(Schro¨dinger) was performed. A chemical diversity (ChemDiv)
library (containing 1,414,000 compounds) and a NCI 2007
plate library (containing117,000 compounds) were searched
for potential small molecule compounds that would bind to the
FZD8 CRDWnt binding site (26).
The initial predocking screening was performed by UNITY
(Tripos, Inc.). A UNITY three-dimensional query was built by
defining the hydrophobic region formed by residues Tyr48,
Ile95, Leu97, Leu147, andMet149 (Fig. 1), all of which are critical
for Wnt-FZD8 CRD binding. After searching both libraries
using UNITY, 5,000 compounds were selected to be docked
into theWnt binding cavity using Glide. By visual inspection of
bound conformations and comparing predicted binding free
energies, we selected the top 40 candidate compounds from the
ChemDiv library and the top 80 compounds from theNCI 2007
plate library as the initial virtual hits. These virtual hits had the
best predicted binding free energies with reasonable bound
conformations.
Five Compounds Show Dose-dependent Inhibition of Wnt3a-
induced Signaling in a Cell Assay—Because theWnt-FZDCRD
interactionmediates canonicalWnt signaling fromupstreamof
the pathway by directly binding to Wnt proteins, a compound
competing with Wnt proteins by binding the FZD CRD with
high affinity will reduce the Wnt--catenin signaling activity.
Wnt3a is the best studied canonical Wnt ligand (27). To test
potential inhibitory effects of compounds selected from VS on
Wnt--catenin signaling, we performed a luciferase-based
screening assay on Wnt-3a mediated reporter gene activity in
3T3 cells (28). Initially, each compound was incubated at two
different concentrations in 3T3 cells transfected with aWnt3a-
conditioned medium that activates the Wnt pathway. Of the
120 compounds tested, five compounds exhibited strong inhi-
bition of Wnt3a-induced responses in a concentration-depen-
dent manner (Fig. 3).
We then explored the dose dependent inhibitory effect of
each compound identified from initial screening in the same
cell-based assay with compound concentration gradients up to
40M and accordingly calculated the IC50 (half-maximal inhib-
itory concentration) values. These results are summarized in
Table 1. The results show that all five compounds have the
capability to inhibit Wnt3a-induced -signaling at the low
FIGURE 3. Inhibition of Wnt signaling by small molecule compounds. A, 3T3 cells were treated with 50 ng/mol recombinant Wnt3a. The level of the
Wnt--catenin pathway response according to luciferase activity was measured in the absence (white bar) or presence of a compound (red bars, ChemDiv
compounds; blue bars, NCI compounds) at two different concentrations. The Wnt activity was normalized against the cells treated with empty vehicle (same
amount of DMSO). Five compounds inhibit the Wnt3a-induced -catenin pathway in a concentration-dependent manner. Ctrl, control. B, chemical structure
of the compounds that inhibited Wnt signaling in the cell-based assay.
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micromolar range dose-dependently (Fig. 4) with compounds
NSC36784 (Fig. 4D) and NSC654259 (Fig. 4E) being the most
potent inhibitors.
All Five Compounds Inhibit LRP6 Phosphorylation Induced
byWnt Signaling—Acritical event in canonicalWnt signaling is
phosphorylation of theWnt co-receptors, LRP5/6. Upon stim-
ulation with Wnt, the intracellular domain LRP6 is phosphor-
ylated at multiple sites including Thr1479, Ser1490, and Thr1493
(29–32). We therefore used the LRP6 phosphorylation as a
marker to further assess the ability of the compounds to inhibit
Wnt signaling. In HEK293T cells, increased phosphorylation
level at Ser1490 of LRP6 could be clearly observed after Wnt3A
treatment.When we added the compounds to the cell cultures,
respectively, we found that comparing to the empty carrier,
DMSO, all five compounds reduced phosphorylation of LRP6
at Ser1490 (Fig. 5) confirming that, indeed, all five compounds
are inhibitors of the canonical Wnt signaling pathway.
All Five Compounds Bind to the FZD CRD at Micromolar
Range—To further evaluate the five compounds, we generated
mouse FZD8 CRD and measured the dissociation constants
(KD) of selected compounds to the FZD8 CRD by BLI experi-
ments. To avoid the low solubility issue of some of the com-
pounds, relatively low concentrations of the compounds were
used in the experiments. For each compound binding to the
biotinylated FZD8 CRD, the binding assays were repeatedmul-
tiple times (all the experiments are reported in Fig. 6), and the
average KD value of each was obtained (Table 1). All five com-
pounds bound to the FZD8 CRD show KD values at low micro-
molar values, which is consistent with the outcomes of cell-
based assay and NMR experiments.
All Five Inhibitors Bind to the Primary Wnt Binding Site on
the FZD8 CRD—We then used NMR spectroscopy to study the
interactions between the five compounds and the FZD8 CRD.
Because the typical required sample concentration for NMR is
relatively high, the issue of compound solubility was addressed
beforeNMRstudieswereperformed. In the study, the compounds
were dissolved in DMSO-d6 to make 10 mM stock solutions. We
made a series of samples with various compound concentrations
in 50 mM potassium phosphate at two different pHs, pH 6.5 and
7.5, with 0.5 mM EDTA, 10% D2O, and 5% DMSO-d6. We then
obtained one-dimensional 1HNMR spectra of each compound at
desired concentrations of 12.5–200 M. The peak intensity
changesof resonance for eachcompoundwere examined todeter-
mine the solubility, as well as visual inspection of precipitation of
compound inbuffer (Figs. 7 and8).The solubilityof compounds in
FIGURE 4.Dose-dependent Inhibition ofWnt3a-induced-catenin signaling by the identified compounds. 3T3 cells were treatedwithWnt3a. A–E, dose
response curves of the inhibitory effect on Wnt/-catenin signaling with five compounds: 3235-0367 (A), 1094-0205 (B), 2124-0331 (C), NSC36784 (D), and
NSC654259 (E). The Wnt activity was normalized against the cells treated with empty vehicle (same amount of DMSO). The IC50 value of each compound is
summarized in Table 1.
TABLE 1
The IC50 value and binding affinity (KD) of compounds tomouse FZD8
CRD by cell-based assays and BLI assays, respectively
Compounds IC50a KDb
M M
3235–0367 7.1
 1.4 2.5
 0.4
1094–0205 5.0
 1.1 3.4
 1.4
2124–0331 10.4
 2.0 2.3
 1.0
NSC36784 6.5
 0.9 3.3
 2.9
NSC654259 5.7
 1.2 2.9
 2.4
a Cell-based assays. Duplicate experiments were performed.
b 50 mM potassium phosphate, pH 6.5, with 0.01% Tween 20, 1 mg/ml BSA.
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the two different buffers was examined. Overall, all five com-
pounds aremore soluble at pH 6.5. Therefore, all theNMRexper-
iments were performed at pH 6.5.
We then performed chemical shift perturbation experiments
to identify the residues of FZD8 CRD involved in binding (33).
The two-dimensional 1H-15N HSQC spectra of 15N-labeled
FZD8 CRD were recorded during the titration of compounds
into a solution of the CRD. All five compounds inducedCSPs in
the 1H-15NHSQCspectra of the FZD8CRD (Fig. 9). Among the
five compounds, NSC654259 showed the largest overall CSPs
in 1H-15NHSQC spectra (Figs. 9 and 10). The signal of residues
Leu97, Met149, and Asp150 of the FZD8 CRD are among those
residues that have chemical shift changes induced by the bind-
ing during the titration of all compounds into the solution of
15N-labeled FZD8 CRD (Fig. 9). As expected, these residues
correspond to the primary protein-protein binding site of the
FZD8 CRD. The signal of residue Leu97 disappeared and reap-
peared upon stepwise addition of compound 3235-0367, indi-
cating that the complex formation is in the intermediate
exchange range on the NMR time scale and the binding affinity
is in the submicromolar range.
Structural Details of the Identified Compounds Binding to the
FZD8 CRD—To better understand of the bindingmode of each
compound, we analyzed the docking structures of identified
compoundswith the data obtained in theCSP experiments.We
first generated a ribbon diagram of the backbone structure of
the FZD8 CRD based on the CSP data (Fig. 11), wherein the
thickness of ribbon is proportional to CSP values observed
FIGURE 5. InhibitionofWnt inducedLRP6phosphorylationby the five identified compounds.A, HEK293T cellswere seeded in a 24-well plate for 24 h and
were then treated withWnt3A CM along or with 10M of the five compounds, as well as DMSO as control, respectively, as indicated for 3 h. The lysates of the
cells were immunoblotted for pLRP6 Ser1490 and tubulin. B, densitometric qualification of pLRP6 Ser1490 normalized to tubulin.
FIGURE 6. BLI binding assays show the binding of five compounds to FZD8 CRD. The SSA sensors with biotinylated mFZD8 CRD were exposed to several
different concentrations (3.1–12.5 M) in 50 mM potassium phosphate, pH 6.5, with 5% DMSO-d6, 0.01% Tween 20, and 1 mg/ml BSA (assay buffer). The
solubility of compound was visually inspected once diluted in the assay buffer. A, 3235-0367. B, 1094-0205. C, 2124-0331. D, NSC36784. E, NSC654259. The
processed data were fitted locally with the integrated fitting function by a 1:1 bindingmode (red line). The respective KD values obtained by curve fitting were
summarized in Table 1.
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upon binding. The ribbon diagram of the FZD8 CRD clearly
shows that all five compounds bind to the primary protein-
protein binding site of the FZD8 CRD. Moreover, we observed
an additional salt bridge forming between the side chain of
Asp150 with the primary amine group of NSC654259 in the
docking model (Fig. 12). This predicted interaction is consis-
FIGURE 7. Solubility test of compounds in phosphate buffer. A–E, 1H NMR spectra of compounds with different desired concentration in 50mM potassium
phosphate, pH 6.5.Orange, 12.5M; yellow, 25M; purple, 50M; green, 100M; red, 150M; blue, 200M. A stock solution of 10mM compoundwas prepared
inDMSO-d6. The arrows are placed to indicate that precipitations of compoundwere observedduring theNMRexperiment at the concentration.A, 3235-0367.
B, 1094-0205. C, 2124-0331. D, NSC36784. E, NSC654259.
FIGURE 8. Solubility test of compounds in phosphate buffer. Relative intensity change of compounds for 1H NMR spectra as a function of concentration in
50mMpotassiumphosphate, pH6.5 (red dots) or pH7.5 (black squares)with 5%DMSO-d6 and10%D2O. From the results,wewere able to estimate the solubility
of each compound. A, 3235-0367; B, 1094-0205; C, 2124-0331; D, NSC36784; E, NSC654259.
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tent with the observation of extra CSP of Asp150 in two-dimen-
sional HSQC spectra (Fig. 9) when titrating NSC654259 with
the FZD8 CRD. Interestingly, each compound induces the dif-
ferent chemical shift perturbations at the residues Leu97,
Lys102, and Asp150 at the FZD8 CRD. This implies that each
compoundmay be in different orientationswhen binding to the
FZD8CRD (Fig. 10). For two compounds, 1094-0205 and 2124-
0331, we also observed some CSPs at the secondary lipid-bind-
ing site of the FZD8 CRD (21) (Fig. 9, B and C). These changes
may be the result of induced conformational change uponbind-
ing of compounds. Overall the predicted docking structures of
the identified compounds are very consistent with two-dimen-
sional HSQC CSP data.
Discussion
Several components of theWnt signaling pathway have been
extensively targeted for the development of new therapeutics to
treat diseases such as cancer (6, 34–37). Lithium, which is a
GSK3 inhibitor, effectively decreases cell proliferation and
induces nonapoptotic cell death in Wnt subtype medulloblas-
toma, in which Wnt signaling is up-regulated by accumulation
of intracellular -catenin (38). Nonsteroidal anti-inflammatory
drugs are also capable of inhibiting Wnt/-catenin pathway
(39). Small molecules regulating canonical Wnt signaling by
targeting the Dishevelled PDZ domain (22, 39, 40) and the
LRP5/6 extracellular domains (26) have also been identified.
In this study, we aim to develop Wnt inhibitors by targeting
FZD. FZD is the first discovered Wnt protein receptor and is
crucial for initiation ofWnt signaling (12). FZDdysregulation is
an important biomarker in many tumor types including lung
and colorectal cancers and hepatocellular carcinoma (18,
41–43). An antibody (OMP-18R5) interacting with FZD extra-
cellular domain directly blocks canonical Wnt signaling and
inhibits the growth and tumorigenicity of multiple human
tumors (9). Here we describe a systematic structure-based
small molecule lead discovery for targeting the FZD8 CRD by
the combination of hierarchical VS, cell-based assays, BLI, and
NMR spectroscopy. From hierarchical VS and cell-based
assays, we identified five compounds capable of inhibiting the
Wnt3a-induced -catenin signaling in the low micromolar
FIGURE9.NMRanalysisof compoundbinding to themouseFZD8CRD.Shownare theextended 1H-15NHSQCspectraof FZD8CRD in theabsence (blue) and
the presence of compound (red). Compounds 3235-0367 (A), 1094-0205 (B), 2124-0331 (C), NSC36784 (D), and NSC654259 (E) were titrated into the solution of
15N-labeled mouse FZD8 CRD, respectively. The insets show the extended two-dimensional 1H-15N HSQC spectra of residue Leu97 at different concentrations
of compound.
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range of IC50 values. We further demonstrated that these com-
pounds antagonize canonical Wnt signaling by binding to the
primaryWnt binding site of the FZD8 CRDwith submicromo-
lar binding affinities from BLI experiments. To our knowledge,
the compounds reported here are the first reported small mol-
ecule canonicalWnt signaling inhibitors that specifically target
the Wnt-FZD CRD interaction.
There are 19 Wnt ligands and 10 FZD receptors in mouse
and human, and the combination of theWnt-FZD interactions
can be complex and functionally redundant, which poses a
challenge for the development of effective inhibitors (9). Not
surprisingly, the sequence alignment ofmouse FZDCRDs indi-
cates that residues in the primary protein-protein binding site
of FZD, which may determine the specificity of the Wnt-FZD
CRD interaction, are diverse (Fig. 1) (21). However, the residues
Leu97, Met149, and Asp150 in the FZD8 CRD, which are critical
for binding, are conserved in many FZD CRDs (Fig. 1). This
suggests that the compounds identified here may also bind to
other FZD receptors, and it would be interesting to see whether
the compounds can indeed target CRDs other than the FZD8
CRD (23, 44). On the other hand, the chemical diversity of the
highly potent small moleculeWnt signaling antagonists identi-
fied also provides an excellent platform for specifically target-
ing individual FZD CRD by lead optimization. Therefore, our
study could be the starting point for the development of an
array of different small molecule inhibitors for different FZD
CRD; and such compounds will be very useful in dissecting
roles of different FZD receptors in different Wnt signaling
pathways.
In the PubChem BioAssay database, it is reported that one of
the compounds we identified, NSC654259, has antitumor
activity in multiple types of tumor cell lines. Although we can-
not rule out that such an antitumor effect is due to its target
other than FDZ CRDs, given that the a monoclonal antibody
that targets the FZD CRDs is able to reduce the growth of dif-
ferent types of tumor (9), the information does lead us to spec-
FIGURE 10. The CSPs of the FZD8 CRD induced by different inhibitors. A, 3235-0367. B, 1094-0205. C, 2124-0331. D, NSC36784. E, NSC654259; F, 2% (v/v)
DMSO.
FIGURE 11. Mapping the binding site of compounds on the FZD8 CRD.
Compounds that bind to the primary protein-protein interaction site of FZD8
CRD. A–E, ribbon representation of the backbone structure of mouse FZD8
CRD in complex with each compound. A, 3235-0367. B, 1094-0205. C, 2124-
0331. D, NSC36784. E, NSC654259. F, 2% DMSO. The backbone thickness of
the ribbon diagram is directly proportional to the weighted sum (in ppm) of
the 1H and 15N chemical shifts on binding to each compound. The program
PyMOL was used to generate all figures.
FIGURE 12. Docking structure of FZD8 CRD with NSC654259. A, ribbon
structure of FZD8 CRD in complex with NSC654259. B, binding surface of
FZD8 CRD in complexwith NSC654259. The hydrophobic residues are shown
in yellow; positive residues are inblue; andnegative charge residues are in red.
C, key residues of FZD8CRDbound toNSC654259 (green, carbon; red, oxygen;
blue, nitrogen) are shown in stick model with labeling. Hydrogen atoms are
omitted for clarification.
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ulate that FZD CRD may be a druggable target of great thera-
peutic potential for treating diseases with aberrant Wnt
signaling. The genetic alteration of Wnt signaling in cancer is
very diverse, making it impractical to develop a single effective
solution for all genetic variations (37). To explore potential
benefits of combinatorial therapy, it is vital to gain access to
compounds targeting multiple important Wnt signaling com-
ponents. The discovery of novel FZD CRD inhibitors may add
important candidates to the Wnt signaling regulator pool and
will be valuable for further understanding Wnt signaling and
discovering most effective therapeutic combinations by target-
ing abnormal Wnt signaling based on genetic profiles of indi-
viduals. Moreover, besides the cost factor associated with anti-
body drugs (45, 46), another advantage of FZD CRD inhibitors
is that theymay have a broader spectrumof the targets; perhaps
a small molecule inhibitor drug can be developed to target
most, if not all, of the 10 human FZDs.
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